R&D Trial complexity is the new normal When operationalised effectively, RBQM can support earlier risk detection and more targeted quality improvement.
News AbbVie charts a new course for CGRPs in menstrual migraine AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.
News Could UK clinical trial revamp unlock closer ties with Canad... Two senior figures in Canada's life science sector have said they see scope for greater collaboration with the UK following clinical trial reforms.
News Amgen's Imdelltra scores again in small cell lung cancer Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.
News BMS eyes role for new CAR-T in post-BCMA multiple myeloma BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.
News FDA starts review of AZ's COPD blockbuster hope The FDA has started a priority review of AstraZeneca's first-in-class IL-33 inhibitor tozorakimab for COPD, setting up a decision in Q1 of 2027.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.